anticoagulants, vitamin K antagonists, acenocoumarol, phenprocoumon
DISEASE INTERVENTION COMPARISON RESULTS
N Engl J Med. 2013 Dec 12;369(24):2304-12 Randomized Controlled Trial, Multicenter Study
IN anticoagulants, vitamin K antagonists, acenocoumarol, phenprocoumon The Use of
pharmacogenetic guided dosing, using CYP2C9 and VKORC1 genotype, combined with clinical information in an algorithm
As Treatment, Acute
Is equal Than
a dosing algorithm that included only clinical variables
To modify the percentage of time that the INR was in the therapeutic range in the first 12 weeks after initiation of therapy